- Market Capitalization, $K 8,572,388
- Shares Outstanding, K 58,110
- Annual Sales, $ 12,990 K
- Annual Income, $ -195,070 K
- 60-Month Beta 1.16
- Price/Sales 371.20
- Price/Cash Flow N/A
- Price/Book 18.40
|Period||Period Low||Period High||Performance|
| || |
-17.86 (-10.80%)since 02/01/21
| || |
+38.57 (+35.41%)since 12/01/20
| || |
+92.53 (+168.33%)since 02/28/20
Even though NIO (NIO) has delivered spectacular returns over the past year, Tencent (TME), Bilibili (BILI), and Zai Lab (ZLAB) have outperformed the stock so far this year. Based on growing market demand...
The biotechnology sector has been the focus of investors since the outbreak of the COVID-19 pandemic. Initially, all eyes were on accurate COVID-19 testing, followed by an anxious wait for vaccines. The...
Bilibili Inc.’s (BILI) entertainment platform enables its users to consume and create content. The company has quickly become quite popular as its user base has increased exponentially due to the coronavirus....
, /PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price is per share; the stock opens...
, /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital,...
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange...
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the "Hong Kong Secondary...
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the "Hong Kong Public...
Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted...
Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will...
|Zai Lab Ltd|
|Chindia ETF FT|
|Global X China Biotech Innovation ETF|
|G-X MSCI China Health Care ETF|
|Etfmg Treatments Testing and Advancements ETF|
|Defiance Nasdaq Junior Biotechnology ETF|
|3rd Resistance Point||157.68|
|2nd Resistance Point||154.28|
|1st Resistance Point||150.90|
|1st Support Level||144.12|
|2nd Support Level||140.72|
|3rd Support Level||137.34|